Hydrocortisone administration
Phase 3Small molecule
Hydrocortisone administration is one of 22 small molecule programs targeting Sepsis. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
308 competitors in Sepsis
#DrugCompanyPhaseTrials
1Hydrocortisone administration
UUniversity of Virginia
Phase 3
Zyvox
PfizerPreclinical
Primaxin
PfizerPreclinical
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Levophed
GGeneral Hospital of Ningxia Medical University
Preclinical
Jardiance
Boehringer IngelheimPreclinical
Micardis
Boehringer IngelheimPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Levaquin
WWim Janssens
Preclinical
Pitocin
RRetrophin
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hydrocortisone1 trial
Administration of Hydrocortisone in Young Healthy Male Volunteers
Completed·—·Phase 4·NCT04137302·21 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Virginia